KMap

Photo of Robin Polt(polt)

Robin Polt

Member of the Graduate Faculty,
Professor, Pharmacology and Toxicology,
Professor, BIO5 Institute,
Professor, Neuroscience - GIDP,
Professor, Chemistry and Biochemistry-Sci,

Chemistry & Biochemistry - Sci
polt@arizona.edu
520/370-2654
UAVitae logo
Grant: $26.0M
Professor Robin Polt began doing chemistry at Indiana University - Purdue University at Indianapolis (IUPUI) on the Vietnam Era GI Bill with Prof. Martin O’Donnell.  At IUPUI he produced the first of the “O’Donnell Schiff bases” that are used to produce unusual and unnatural amino acids.  This methodology now appears in many undergraduate textbooks for Organic Chemistry and is widely used in industry.  While at IUPUI he was awarded a National Science Foundation Pre-Doctoral Fellowship.  Polt earned his Ph.D. at Columbia University in NYC with Prof. Gilbert J. Stork, one of the founders of Syntex Corp which introduced the first oral contraceptives in the late 1950s.  He completed his training in the art of Organic Synthesis with Prof. Dieter Seebach at the ETH in Zürich, Switzerland before coming to the University of Arizona in 1988.   Polt has continued to develop novel synthetic methods for amino acids, amino alcohols, glycosides and glycopeptides.  Application of these methods has resulted in the production of a number of pharmacologically active glycopeptides, alkaloid-like inhibitors of glycolipid processing enzymes and glycosyltransferases, as well as glycolipids with biological activity such as glycosphingolipids and rhamnolipids.  He discovered a new class of glycosphingolipids in the insect Manduca sexta— biologically active sphingomyelins and glycosides derived from dienylsphingosine, and he has developed methods for their synthesis, as well as the synthesis of rhamnolipids from Pseudomonas aeruginosa.  The biological focus of his work has been in attempting to understand the chemistry of carbohydrates (glycolipids & glycopeptides) at cell membranes, membrane trafficking, and using these insights to design glycopeptide drugs from endogenous peptide neurotransmitters (neuromodulators, hormones) with enhanced stability in vivo that are capable of penetrating the Blood-Brain Barrier.  In addition to lecturing and laboratory teaching he has mentored a large number of undergraduate, graduate (19 Ph.D.s   His Ph.D.s have hailed from the US (10), Czech Republic*, China, India, Iran*, Ireland, Kenya*, Korea, Mexico* and Sri Lanka.  Four of these Ph.D. students (*) have gone on to become naturalized citizens or permanent resident status.  Recent undergraduates associated with Polt’s research group have gone to graduate schools at Harvard, MIT, Boston University, University of Wisconsin, and Columbia University.  Polt’s research has been supported by the National Science Foundation (NSF), the National Institute of Neurological Disease and Stroke (NINDS), the US Army, the Office of Naval Research (ONR), the Michael J. Fox Foundation and the Migraine Research Foundation, in addition to industrial support, now totalling over $15M.  His current research work is supported by NINDS and is directed toward the development of neuroprotective drugs for Parkinson’s Disease from endogenous neuropeptides, as well as NSF-EPA studies done in collaboration with the Pemberton group on the development of "green" surfactants. We have recently begun collaboration with Joe Garcia's group at the Medical School on the development of Sphingosine-1-Phosphate receptor agonists for the treatment of lung injury.  We have submitted a new RO1 to NIH to support this work. Besides Jeanne Pemberton's GlycoSurf start-up, which was based on "Polt technology" licensed to them, a second start-up owned by Meredith Hay called ProNeurogen has licensed IP from us regarding glycosylated angiotensin analogues as neuroprotective compounds, and one of these compounds is now entering clinical trials for the treatment of post-surgical dementia.  Note that I have no equity position in either of these companies, but I do retain 17% ownership in our Deleware based company, Biousian Biosystems, Inc.  Further, we are starting a new company called Teleport Pharmaceuticals in order to exploit our chemistry to produce centrally active drugs based on peptide neurotransmitters.
Robin Polt experts in organic chemistry, pharmacology, neuroscience, biomaterials, drug delivery, anesthesiology, biochemistry, medicinal chemistry, inorganic chemistry, organometallic chemistry, catalysis, glycobiology, bioinformatics, computational biology, tissue engineering, organic synthesis, neuropharmacology, pharmaceutics, bioinorganic chemistry, astronomy, astrophysics, analgesia, molecular biology, structural biology, nmr spectroscopy, biophysics, entomology, microbiology, x-ray crystallography, theoretical chemistry, glycosylation, molecular dynamics simulation, glycosyltransferases, supramolecular chemistry, insect physiology, chemical biology, neuropsychopharmacology, chemistry, glycosphingolipids, enzymology, psychiatry, physical chemistry, spectroscopy, biodegradable polymers, microbial ecology, pulmonary hypertension, lung cancer, nanomedicine, neuroprotection, neurodegenerative diseases
Courses
Advanced Laboratory Safety 
Chemical Hygiene and Regulations 
Introduction to Pharmacology and Toxicology Research 
Advanced Synthetic Organic Chemistry 
Lectures in Organic Chemistry 
Synthetic and Mechanistic Organic Chemistry 
Organic Preparations 
Advanced Organic Chemistry 
Introduction to Pharmacology, Drug Discovery & Pharmaceutics 
Basic Laboratory Safety 
Recent Grants
Logo of Oxytocin Analgesics Without Side Effects for Opioid Use Disorder funding agency
2022 $100.0KActive
Oxytocin Analgesics Without Side Effects for Opioid Use Disorder
Logo of Development of a Selective Mu-Delta Opioid Receptor Heterodimer Antagonist for Enhancing Opioid Analgesia while Reducing Side Effects funding agency
2021 $499.4KActive
Development of a Selective Mu-Delta Opioid Receptor Heterodimer Antagonist for Enhancing Opioid Analgesia while Reducing Side Effects
Logo of Glycosylated Endomorphin Analogs for Treatment of Opioid Use Disorder (OUD) funding agency
2021 $46.0KActive
Glycosylated Endomorphin Analogs for Treatment of Opioid Use Disorder (OUD)
Logo of IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia funding agency
2020 $6.5MActive
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia
Logo of IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia funding agency
2020 $128.2KActive
IND Enabling Studies for a Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Alzheimer's Disease Related Dementia
Logo of MOR/DOR Heterodimer Antagonists: A Novel Treatment for Opioid Dependence funding agency
2019 $1.2M
MOR/DOR Heterodimer Antagonists: A Novel Treatment for Opioid Dependence
Logo of PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease funding agency
2015 $2.0M
PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease
Logo of PACAP Antagonists as Novel Migraine Therapies funding agency
2014 $25.0K
PACAP Antagonists as Novel Migraine Therapies
Logo of NSMDS: Molecular Design, Synthesis and Characterization of Green Glycolipid Surfactants funding agency
2013 $4.5M
NSMDS: Molecular Design, Synthesis and Characterization of Green Glycolipid Surfactants
Logo of Opioid glycopeptides for the treatment of levodopa-induced dyskinesia funding agency
2012 $75.0K
Opioid glycopeptides for the treatment of levodopa-induced dyskinesia
Technologies / Patents
Logo of Micelles And Vesicles For The Delivery Of Glycopeptides
2022Micelles And Vesicles For The Delivery Of Glycopeptides 
Logo of ANG(1-7) Derivative Oligopeptides And Methods For Using And Producing The Same
2021ANG(1-7) Derivative Oligopeptides And Methods For Using And Producing The Same 
Logo of ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain
2021ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain 
Logo of Carbohydrate-Based Surfactants
2021Carbohydrate-Based Surfactants 
Logo of Ang-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same
2020Ang-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same 
Logo of Glycosylated Peptides With Pseudoproline Residues And Having Enhanced Half-Lives And Ability To Cross The Blood Brain Barrier
2020Glycosylated Peptides With Pseudoproline Residues And Having Enhanced Half-Lives And Ability To Cross The Blood Brain Barrier 
Logo of ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain and Other Indications
2019ANG-(1-7) Derivative Oligopeptides for the Treatment of Pain and Other Indications 
Logo of Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases
2018Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases 
Logo of Ang-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same
2017Ang-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same 
Logo of ANG-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same
2017ANG-(1-7) Derivative Oligopeptides and Methods for Using and Producing the Same 
Logo of Carbohydrate-Based Surfactants
2016Carbohydrate-Based Surfactants 
Logo of Amphipathic Glycopeptides
2010Amphipathic Glycopeptides 
Logo of Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases
1899Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases 
Logo of Glycopeptides Analgesics
1899Glycopeptides Analgesics 
Logo of Glycosylated Peptides with Pseudoproline Residues and Having Enhanced Half-Lives and Ability to Cross the Blood Brain Barrier
1899Glycosylated Peptides with Pseudoproline Residues and Having Enhanced Half-Lives and Ability to Cross the Blood Brain Barrier 
News
2022Following nature's rules, researchers develop new methods for treating degenerative neurological disease  
2017UA Startup Advances New Therapies for Vascular Dementia 
2015UA Research goes from Idea to Patent to Market 
2014Catapulting UA Discoveries to the World 
2013UA Pain Research Team Awarded $2.5M to Tackle Chronic Pain 
2009UA Student Earns Howard Hughes Award 
2007Interdisciplinary UA, NAU Team Receives $3.3 million to Study Biosurfactants 
2007Valley Fever Drug Phase 1 and 2 Clinical Trial Funded  
UArizona reports record number of inventions 
Publications (116)
Recent
2022Design and Synthesis of Novel Brain Penetrant Glycopeptide Analogues of PACAP with Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism. 
2021Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers. 
2021Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides. 
2020Glycopeptide drugs: A pharmacological dimension between Small Molecules and Biologics . 
2020Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model. 
2020In silico Docking Studies of Fingolimod and S1P1 Agonists. 
2020Lessons in Stereochemistry: Resolution, Synthesis, and Characterization of Chiral Compounds 
2020The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia 
2020Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration 
2020Sphingosine-1-phosphate receptor-independent lung endothelial cell barrier disruption induced by FTY720 regioisomers. 
2020Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. 
2020Biodegradability and toxicity of cellobiosides and melibiosides 
2020Characterization of Delta Opioid Receptor Activity of MMP2200, a Mixed Efficacy Mu and Delta Opioid Receptor Agonist 
2019Biodegradability and toxicity of monorhamnolipid biosurfactant diastereomers 
2018The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia 
2018An update on sphingosine-1-phosphate receptor 1 modulators. 
2017Synthesis and Characterization of Four Diastereomers of Monorhamnolipids 
2017The opioid glycopeptide MMP-2200: Analysis in preclinical models of L-DOPA-induced dyskinesia 
2016Preparation of S-Glycoside Surfactants and Cysteine Thioglycosides 
2016Alkyl-melibioside and Alkyl-cellobioside Solution Phase Properties: Effect of Sugar Headgroup and Alkyl Chain Length on Surfactant Performance 
2015The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence 
2015Glycolipids and glycopeptides: Minimally competent Lewis acid catalysis produces surfactants for use ex vivo and in vivo 
2015CNS active O-linked glycopeptides. 
2015Structural Requirements for CNS Active Opioid Glycopeptides 
2014Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin? 
2013A PM-IRRAS Investigation of Monorhamnolipid Orientation at the Air-Water Interface 
2012Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins 
2012Glycosylation of α-amino acids by sugar acetate donors with InBr3. Minimally competent Lewis acids 
2012Glycosylation of α-amino acids by sugar acetate donors with InBr sub 3 /sub . Minimally competent Lewis acids 
2012Minimally Competent Lewis Acid Catalysts: Indium(III) and Bismuth(III) Salts Produce Rhamnosides (=6‐Deoxymannosides) in High Yield and Purity 
2012CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis study 
2011Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments 
2011(S)-Methyl 2-{(S)-2-[bis(4-methoxyphenyl)methylideneamino]-3- hydroxypropanamido}-3-methylbutanoate 
2011In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice 
2011Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease. 
2010Serine and threonine Schiff base esters react with β-anomeric peracetates in the presence of BF sub 3 /sub ·Et sub 2 /sub O to produce β-glycosides 
2010(S)-Methyl 2-{(S)-2-[bis-(4-meth-oxy-phen-yl)methyl-idene-amino]-3-hy-droxy-propanamido}-3-methyl-butano-ate. 
2010Synthetic Method for the Development of Monorhamnolipids 
2009Glycosyl-enkephalins: synthesis and binding at the mu, delta kappa opioid receptors. Antinociception in mice 
2009Assessment of the efficacy and side effect profile of morphine and MMP2200, a mixed delta/mu agonist 
2008Behavioral pharmacology of the μ/δ opioid glycopeptide MMP2200 in rhesus monkeys 
2008Endoglycosidases: Biochemistry, Biotechnology, Application Edited by Masahiko Endo (Hirosaki University, Aomori, Japan), Sumihiro Hase (Osaka University, Osaka, Japan), Kenji Yamamoto (Kyoto University, Kyoto, Japan), and Keiichi Takagaki (Hirosaki University School of Medicine, Aomori, Japan). Kodansha Ltd: Tokyo and Springer: Berlin, Heidelberg, New York. 2006. xvi + 255 pp. $169.00. ISBN 4-06-212192-2 (Kodansha) and 3-540-34494-2 (Springer). 
2008Structural studies on the neutral glycosphingolipids of Manduca sexta. 
2007Sugar synthesis from a gas-phase formose reaction 
2007Glycosylation improves the central effects of DAMGO 
2006Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability 
2005Biousian glycopeptides penetrate the blood-brain barrier 
2005N-DIPHENYLMETHYLENE-PROTECTED GLYCOSYL ACCEPTORS - SELECTIVE BETA-O-GLYCOSYLATION TO FORM LACTOSYL-THREO-CERAMIDES 
2005New prospects for glycopeptide based analgesia: glycoside-induced penetration of the blood-brain barrier 
2005Glycosylated neuropeptides: A new vista for neuropsychopharmacology? 
2005Glycopeptides related to beta-endorphin adopt helical amphipathic conformations in the presence of lipid bilayers 
2005Improved bioavailability to the brain of glycosylated Met-enkephalin analogs 
2005INVESTIGATING THE INTERSTELLAR CHEMISTRY LEADING TO SIMPLE SUGARS 
2004New PDMP analogues inhibit process outgrowth in an insect cell line 
2004Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. 
2004BETA-AMINO ALCOHOLS FROM AMINO-ACIDS - CHELATION CONTROL VIA SCHIFF-BASES 
2004Presence of unsaturated sphingomyelins and changes in their composition during the life cycle of the moth Manduca sexta 
2003Optically active 4- and 5-coordinate transition metal complexes of bifurcated dipeptide Schiff bases 
2003Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media 
2003GLYCOPEPTIDE ENKEPHALIN ANALOGS PRODUCE ANALGESIA IN MICE - EVIDENCE FOR PENETRATION OF THE BLOOD-BRAIN-BARRIER 
2002Deprotonation of Chelating Enamines. Direct Formation of β‐Lithio Enamines. 
2001O-linked glycopeptides retain helicity in water 
2001Solid-phase synthesis of O-linked glycopeptide analogues of enkephalin. 
2001Glycopeptide analgesics 
2001Lipo α-amino-β-hydroxy acids and O-linked glycosides: Building blocks for ceramyl and glycosphingoyl peptides 
2000Lipid Synthesis and Manufacture Edited by Frank D. Gunstone (Professor Emeritus, University of St. Andrews, Dundee, Scotland). CRC Press: Boca Raton. 1999. xv + 472 pp. $135.00. ISBN 0-8493-9737-5. 
2000Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides 
2000ALKYLATION OF IMIDAZOLIDINONE DIPEPTIDE DERIVATIVES - PREPARATION OF ENANTIOMERICALLY PURE DIPEPTIDES AND TRIPEPTIDES BY CHIRALITY TRANSFER VIA A PIVALALDEHYDE N,N-ACETAL CENTER 
2000Asymmetric syntheses of (-)-8-epi-swainsonine triacetate and (+)-1,2-di-epi-swainsonine. Carbonyl addition thwarted by an unprecedented aza-pinacol rearrangement 
2000AN ENANTIOSELECTIVE SYNTHESIS OF N-METHYLFUCOSAMINE VIA TANDEM C-C C-O BOND FORMATION 
2000Enkephalin-based drug design: conformational analysis of O-linked glycopeptides by NMR and molecular modeling 
2000Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. 
2000Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. 
1999Glycosidase inhibitors: Synthesis of enantiomerically pure aza-sugars from Schiff base amino esters via tandem reduction-alkenylation and osmylation 
1998Glycosyltransferase inhibitors: Synthesis of D-threo-PDMP, L-threo- PDMP, and other brain glucosylceramide synthase inhibitors from D- or L- serine 
1998SYNTHESES OF IMINOLYXITOLS VIA TANDEM REDUCTION-ALKENYLATION OF O DONNELL S SCHIFF BASES 
1998Syntheses of iminolyxitols via tandem reduction-alkenylation of O'Donnell's Schiff bases 
1997STEREOSELECTIVE SYNTHESIS OF O-SERINYL/THREONINYL-2-ACETAMIDO-2-DEOXY-ALPHA-GLYCOSIDES OR O-SERINYL/THREONINYL-2-ACETAMIDO-2-DEOXY-BETA-GLYCOSIDES 
1997Amino acid-derived ligands for transition metals: Catalysis via a minimalist interpretation of a metalloprotein 
1997General method for the synthesis of N-methyl amino acids and N-alkyl amino esters from O'Donnell's Schiff bases 
1996New chemical method for synthesis of O-linked glycopeptides 
1995Piperidine Triols via Enantioselective Alkylation and Osmylation of Alanine Schiff Base Esters 
1995Stereoselective synthesis of O-serinyl/threoninyl-2-acetamido-2-deoxy-α- or β-glycosides 
1995DESIGN AND SYNTHESIS OF PEPTIDE LIGANDS WITH UNIQUE BIOCHEMICAL AND BIOLOGICAL PROFILES AT OPIOID RECEPTORS THAT CROSS THE BLOOD BRAIN BARRIER 
1995Preparation of monosilyl acetals from esters via iBu sub 2 /sub AlH reduction and trapping with N-(trimethylsilyl)imidazole. Addition of allyltrimethylsilane to yield homoallylic alcohols or ethers 
1994A systematic study of glycolaldehyde in sagittarius B2(N) at 2 and 3 mm: Criteria for detecting large interstellar molecules 
1994An enantioselective synthesis of N-methylfucosamine via tandem C-C/C-O bond formation 
1994Stereoselective synthesis of β-D-glycopyranosyl-L-serinate or - threoninate derivatives with an unusual migration 
1994ASSESSMENT OF AN IN-VITRO BLOOD-BRAIN-BARRIER MODEL USING SEVERAL [MET5]ENKEPHALIN OPIOID ANALOGS 
1994Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. 
1994New opioid compounds in analgesia 
1993Determination and metabolism of dithiol chelating agents. XV. The meso- 2,3-dimercaptosuccinic acid-cysteine (1:2) mixed disulfide, a major urinary metabolite of DMSA in the human, increases the urinary excretion of lead in the rat 
1993GENERAL-METHODS FOR ALPHA-O-SER/THR OR BETA-O-SER/THR GLYCOSIDES AND GLYCOPEPTIDES - SOLID-PHASE SYNTHESIS OF O-GLYCOSYL CYCLIC ENKEPHALIN ANALOGS 
1993β-Alkoxy Schiff base–oxazolidine tautomerism: solid-state structure of N-diphenylmethylene-l-threonine methyl ester 
1993N-diphenylmethylene-protected glycosyl acceptors. Selective β-O-glycosylation to form lactosyl-threo-ceramides 
1993O-GLYCOPEPTIDES - A SIMPLE BETA-STEREOSELECTIVE GLYCOSIDATION OF SERINE AND THREONINE VIA A FAVORABLE HYDROGEN-BONDING PATTERN 
1993Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs. 
1992Catalysis by amino acid-derived tetracoordinate complexes: Enantioselective addition of dialkylzincs to aliphatic and aromatic aldehydes 
1992General Methods for α- or β-O-Ser/Thr Glycosides and Glycopeptides. Solid-Phase Synthesis of O-Glycosyl Cyclic Enkephalin Analogues 
1992Aluminoxy acetals from α-amino esters: Chirality transfer via sequential addition of hydride and C-nucleophiles. 2-Amino alcohols and sphingosines 
1992E-1-LITHIO-1-ALKENES IN HYDROCARBON SOLVENT 
1992A synthetic method for unsymmetrical disulfides of cysteine: the bis-cysteine disulfide of meso-2,3-dimercaptosuccinic acid. 
1991Erythrose sesqui-acetals as electrophiles. 2-Deoxy-C-nucleosides from D-glucose. 
1991Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation 
1991O-glycopeptides: a simple β-stereoselective glycosidation of serine and threonine via a favorable hydrogen bonding pattern. 
1990β-Amino alcohols from amino acids: Chelation control via schiff bases. 
1989Stereoselective alkylation of glycine units in dipeptide derivatives: Chirality transfer via a pivalaldehyde N,N-acetal center 
1988Theoretical studies of the lithiation of enamines 
1988Acidities of glycine Schiff bases and alkylation of their conjugate bases 
1987Alkylation of Imidazolidinone Dipeptide Derivatives: Preparation of Enantiomerically Pure Di‐ and Tripeptides by ‘Chirality Transfer’ via a Pivalaldehyde N,N‐Acetal Center. Preliminary Communication 
1987STEREOSELECTIVE ALKYLATION OF GLYCINE UNITS IN DIPEPTIDE DERIVATIVES - CHIRALITY TRANSFER VIA A PIVALALDEHYDE N,N-ACETAL CENTER 
1986Deprotonation of chelating enamines. Direct formation of β-lithio enamines 
1985Preparation of an electrophilic glycine cation equivalent and its reaction with heteroatom nucleophiles 
1985Preparation of an Electrophilic Glycine Cation Equivalent and Its Reaction with Heteroatom Nucleophiles. The Synthesis of Amino Acids by Reaction of an Electrophilic Glycine Cation Equivalent with Carbon Nucleophiles. 
1984X-ray crystal structure of N-(2-lithiocyclohexenyl)-N,N′,N′-trimethyl-1,3-propanediamine: A pentavalent lithium? 
1982A mild and efficient route to Schiff base derivatives of amino acids 
Grants
Citations
H-Index
Tech
Patents
News
Books
Opportunities